Mangoceuticals Develops Oral GLP-1s: Stock Soars
Mangoceuticals Develops Oral GLP-1s: Stock Soars
Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher Tuesday after the company announced the development of oral formulations of Semaglutide and Tirzepatide.
Mangoceuticals, Inc.（納斯達克股票代碼：MGRX）週二股價走高，此前該公司宣佈開發索瑪魯肽和替塞帕肽的口服制劑。
The Details:
細節：
Mangoceuticals announced the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("Trim") to aid in weight management. The company plans to have the products available for customers in the beginning of the 3rd quarter with 'Slim' and 'Trim' priced at $299/month and $399/month, respectively.
Mangoceuticals宣佈開發Semaglutide（“Slim”）和替塞帕肽（“Trim”）的專有口服制劑，以幫助控制體重。該公司計劃在第三季度初向客戶提供這些產品，“Slim” 和 “Trim” 的價格分別爲每月299美元和每月399美元。
"We are thrilled to introduce 'Slim' and 'Trim', MangoRx's oral formulations of Semaglutide and Tirzepatide, to the weight loss market," said Jacob Cohen, CEO of MangoRx.
MangorX首席執行官雅各布·科恩表示：“我們很高興向減肥市場推出'Slim'和'Trim'，即MangorX的索瑪魯肽和替塞帕肽口服制劑。”
"Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide."
“我們的目標是爲患者提供一種便捷有效的方法來控制體重和改善他們的整體健康狀況。我們認爲，這些口服配方有可能對全球數百萬人的生活產生重大影響。”
Mangoceuticals shares are racing higher on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 102 million shares have already been traded in the session, compared to the stock's 100-day average of less than 574,000 shares.
宣佈後，由於交易量龐大，Mangoceuticals的股價正在上漲。根據Benzinga Pro的數據，該交易日已經交易了超過1.02億股股票，而該股的100天平均交易量不到57.4萬股。
Related News: Palo Alto Networks Shares Drop After Q3 Results, In-Line Guidance: The Details
相關新聞： 帕洛阿爾託網絡股價在第三季度業績公佈後下跌，行內指導：詳情
Is MGRX A Good Stock To Buy?
MGRX 是一隻值得買入的好股票嗎？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Mangoceuticals' page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投資者在決定股票是否值得買入時可以做出一些決定。除了可以在Benzinga的報價頁面（例如Mangoceuticals的頁面）上找到的估值指標和價格走勢外，還有一些因素，例如公司是否每季度支付股息或購買大部分股票。
These are known as capital allocation programs. Mangoceuticals does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
這些被稱爲資本分配計劃。Mangoceuticals不支付股息，但顯然有幾種方法可以向股東返還價值。您可以隨時在Benzinga的股息日曆中搜索下一家即將派發股息的公司，並確定持有該公司股份可以獲得什麼樣的收益率。
For example, if you're looking to earn an annualized return of 12.46%, you'll need to buy a share of Big Banc Split by May 29, 2024. Once done, you can expect to receive a nominal payout of $0.12 on June 14, 2024.
例如，如果您希望獲得12.46％的年化回報率，則需要在2024年5月29日之前購買Big Banc Split的股份。完成後，您預計將在2024年6月14日收到0.12美元的名義補助金。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Mangoceuticals will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回購計劃顯然是不同的，而且變化很大。公司可以批准回購計劃，並在回購獲得批准的時間內酌情購買股票。查看Mangoceuticals的最新消息通常可以得出該公司最近是否批准了回購計劃。回購計劃通常作爲股價的支撐，作爲需求的支撐。
MGRX Price Action: According to Benzinga Pro, Mangoceuticals shares are up 247% at 88 cents at the time of publication Tuesday.
MGRX價格走勢：根據Benzinga Pro的數據，截至週二發佈時，Mangoceuticals的股價上漲了247％，至88美分。
Image created using artificial intelligence via Midjourney
通過 Midjourney 使用人工智能創建的圖像
譯文內容由第三人軟體翻譯。